跳至主要内容
临床试验/NCT04441892
NCT04441892终止不适用

Phase II Novel Low Cost QTc Meter for Long QT Syndrome Screening in Primary Care

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2019年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Mayo Clinic
入组人数
33
试验地点
2
主要终点
Low Cost QTc Meter for Long QT Syndrome Screening

研究概览

简要总结

The purpose of this study is to further develop and evaluate a diagnostic procedure suitable for use in an inexpensive diagnostic instrument suitable for screening for Long QT Syndrome (LQTS) in the primary care environment.

详细描述

The study will involve acquiring ECG data in a cohort of up to 1,000 newborns and infants (500 controls (non-LQTS) and 500 LQTS newborns and infants) that are being seen in the Gonda SL ECG Lab (or Baldwin Building)and enrolled during their appointment for a clinically indicated 12-lead ECG. A second arm of Phase II of this study will include approaching 50 healthy subjects at the Baldwin Building to seek interest in participation which will consist of (1) 30 second device recording to help further calibrate and test the device for optimal enhancement. These 50 subjects will not be required to have a clinical or research 12-lead ECG as the investigators will be simply testing the efficiency and accuracy of the device. LQTS will be studied in order to assess the ability of the LQTS screener to accurately detect a patient with established QT prolongation in the context of distinct and varied T wave morphologies The advanced prototype will be placed in the same manner as the device used in Phase I of the study by being lightly placed on the child as pictured below. Similarly, the investigators will use ultrasound gel to obtain a better reading, if applicable. Once completed, a photograph of the torso of the child will be taken from the same views as before (one aerial view and one side view) with neither the head nor the face in the picture. Coded ECG-tracings will be transmitted to the app and shared with Blue Ox Health Corporation and Minnesota Health Solutions as done previously in phase I. Additionally, coded tracings and data from the 12-lead ECG will be shared with Blue Ox Health Corporation and Minnesota Health Solutions to aid in comparison to device tracings and optimization of the algorithm. The 12-lead ECG will be obtained from the subject's medical record and coded before being shared with collaborators. Study coordinators will also review the patient's medical record to determine whether the participants have been diagnosed with a genetic disease.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
— 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Infants (Day 0 - 5 years).
  • Long QT Syndrome(LQTS).
  • Newborns without LQTS (Controls).
  • Parental willingness to provide informed consent and follow the study protocol.

排除标准

  • Children > 5 years old.
  • Those with genetically elusive LQTS.
  • Infants with congenital heart disease.
  • Infants born < 32 weeks EGA.
  • Patients with a cardiac device implant (pacemaker/ICD).

结局指标

主要结局

Low Cost QTc Meter for Long QT Syndrome Screening

时间窗: Baseline

Number of subjects to have a successful tracing recorded with the QTc Meter in Participants with or without Long QT Syndrome between the ages of 0 and 5

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael J. Ackerman

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验